Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors

Fausto Rossini, Pietro Pioltelli, Silvia Mingozzi, Rino Bregani, Franco Viganó, Silvia Bolis, Ivana Casaroli, Eraldo Lanzi, Enrico M. Pogliani, Gianmarco Corneo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This study aimed to evaluate the efficacy of amikacine and ceftazidime as an empirical antibiotic therapy for neutropenic patients affected by haematological neoplasms and to investigate the presence of prognostic features suggesting a poor outcome with this antibiotic combination at the onset of infection. This could allow the identification of subgroups of patients with a low rate of response to amikacin/ceftazidime therapy; in these patients different initial empirical therapy may be indicated. The study population comprised 166 severely neutropenic (absolute neutrophil count below 500/μl) oncohaematological patients with fever or clinical signs of infection. Multivariate analysis confirmed four negative prognostic factors: 3 or more days of hospitalization at the onset of an infectious episode, a diagnosis of acute myeloid leukaemia, a haematological disease status different from complete remission, the presence of pneumonia. Depending on how many factors are present, cases can be stratified into three groups, of significantly different prognosis: favourable (0 or 1 factor) 76% success; intermediate (2 factors) 52% success; unfavourable (3 or 4 factors) 19% success. At the onset of an infectious episode a subgroup of patients with a very low response rate to empirical amikacin/ceftazidime antibiotic therapy is identifiable, for whom a different therapy is indicated. Because of the high rate of proven or probable fungal infections in this group, the immediate administration of a systemic antifungal therapy, in addition to antibacterial agents, could be considered in these high-risk patients. Studies should be specifically addressed to evaluating a stratification of empirical antibiotic therapy according to risk factors present at the onset of infection.

Original languageEnglish
Pages (from-to)259-265
Number of pages7
JournalSupportive Care in Cancer
Volume2
Issue number4
DOIs
Publication statusPublished - Jul 1994

Fingerprint

Ceftazidime
Amikacin
Anti-Bacterial Agents
Therapeutics
Infection
Mycoses
Hematologic Diseases
Hematologic Neoplasms
Acute Myeloid Leukemia
Pneumonia
Hospitalization
Neutrophils
Fever
Multivariate Analysis
Population

Keywords

  • β-Lactamic-aminoglycoside combinations
  • Febrile neutropenic cancer patients
  • Infection

ASJC Scopus subject areas

  • Nursing(all)
  • Oncology

Cite this

Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients : analysis of prognostic factors. / Rossini, Fausto; Pioltelli, Pietro; Mingozzi, Silvia; Bregani, Rino; Viganó, Franco; Bolis, Silvia; Casaroli, Ivana; Lanzi, Eraldo; Pogliani, Enrico M.; Corneo, Gianmarco.

In: Supportive Care in Cancer, Vol. 2, No. 4, 07.1994, p. 259-265.

Research output: Contribution to journalArticle

Rossini, F, Pioltelli, P, Mingozzi, S, Bregani, R, Viganó, F, Bolis, S, Casaroli, I, Lanzi, E, Pogliani, EM & Corneo, G 1994, 'Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors', Supportive Care in Cancer, vol. 2, no. 4, pp. 259-265. https://doi.org/10.1007/BF00365733
Rossini, Fausto ; Pioltelli, Pietro ; Mingozzi, Silvia ; Bregani, Rino ; Viganó, Franco ; Bolis, Silvia ; Casaroli, Ivana ; Lanzi, Eraldo ; Pogliani, Enrico M. ; Corneo, Gianmarco. / Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients : analysis of prognostic factors. In: Supportive Care in Cancer. 1994 ; Vol. 2, No. 4. pp. 259-265.
@article{b362500754f44ec0802964d2e5c5afde,
title = "Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors",
abstract = "This study aimed to evaluate the efficacy of amikacine and ceftazidime as an empirical antibiotic therapy for neutropenic patients affected by haematological neoplasms and to investigate the presence of prognostic features suggesting a poor outcome with this antibiotic combination at the onset of infection. This could allow the identification of subgroups of patients with a low rate of response to amikacin/ceftazidime therapy; in these patients different initial empirical therapy may be indicated. The study population comprised 166 severely neutropenic (absolute neutrophil count below 500/μl) oncohaematological patients with fever or clinical signs of infection. Multivariate analysis confirmed four negative prognostic factors: 3 or more days of hospitalization at the onset of an infectious episode, a diagnosis of acute myeloid leukaemia, a haematological disease status different from complete remission, the presence of pneumonia. Depending on how many factors are present, cases can be stratified into three groups, of significantly different prognosis: favourable (0 or 1 factor) 76{\%} success; intermediate (2 factors) 52{\%} success; unfavourable (3 or 4 factors) 19{\%} success. At the onset of an infectious episode a subgroup of patients with a very low response rate to empirical amikacin/ceftazidime antibiotic therapy is identifiable, for whom a different therapy is indicated. Because of the high rate of proven or probable fungal infections in this group, the immediate administration of a systemic antifungal therapy, in addition to antibacterial agents, could be considered in these high-risk patients. Studies should be specifically addressed to evaluating a stratification of empirical antibiotic therapy according to risk factors present at the onset of infection.",
keywords = "β-Lactamic-aminoglycoside combinations, Febrile neutropenic cancer patients, Infection",
author = "Fausto Rossini and Pietro Pioltelli and Silvia Mingozzi and Rino Bregani and Franco Vigan{\'o} and Silvia Bolis and Ivana Casaroli and Eraldo Lanzi and Pogliani, {Enrico M.} and Gianmarco Corneo",
year = "1994",
month = "7",
doi = "10.1007/BF00365733",
language = "English",
volume = "2",
pages = "259--265",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients

T2 - analysis of prognostic factors

AU - Rossini, Fausto

AU - Pioltelli, Pietro

AU - Mingozzi, Silvia

AU - Bregani, Rino

AU - Viganó, Franco

AU - Bolis, Silvia

AU - Casaroli, Ivana

AU - Lanzi, Eraldo

AU - Pogliani, Enrico M.

AU - Corneo, Gianmarco

PY - 1994/7

Y1 - 1994/7

N2 - This study aimed to evaluate the efficacy of amikacine and ceftazidime as an empirical antibiotic therapy for neutropenic patients affected by haematological neoplasms and to investigate the presence of prognostic features suggesting a poor outcome with this antibiotic combination at the onset of infection. This could allow the identification of subgroups of patients with a low rate of response to amikacin/ceftazidime therapy; in these patients different initial empirical therapy may be indicated. The study population comprised 166 severely neutropenic (absolute neutrophil count below 500/μl) oncohaematological patients with fever or clinical signs of infection. Multivariate analysis confirmed four negative prognostic factors: 3 or more days of hospitalization at the onset of an infectious episode, a diagnosis of acute myeloid leukaemia, a haematological disease status different from complete remission, the presence of pneumonia. Depending on how many factors are present, cases can be stratified into three groups, of significantly different prognosis: favourable (0 or 1 factor) 76% success; intermediate (2 factors) 52% success; unfavourable (3 or 4 factors) 19% success. At the onset of an infectious episode a subgroup of patients with a very low response rate to empirical amikacin/ceftazidime antibiotic therapy is identifiable, for whom a different therapy is indicated. Because of the high rate of proven or probable fungal infections in this group, the immediate administration of a systemic antifungal therapy, in addition to antibacterial agents, could be considered in these high-risk patients. Studies should be specifically addressed to evaluating a stratification of empirical antibiotic therapy according to risk factors present at the onset of infection.

AB - This study aimed to evaluate the efficacy of amikacine and ceftazidime as an empirical antibiotic therapy for neutropenic patients affected by haematological neoplasms and to investigate the presence of prognostic features suggesting a poor outcome with this antibiotic combination at the onset of infection. This could allow the identification of subgroups of patients with a low rate of response to amikacin/ceftazidime therapy; in these patients different initial empirical therapy may be indicated. The study population comprised 166 severely neutropenic (absolute neutrophil count below 500/μl) oncohaematological patients with fever or clinical signs of infection. Multivariate analysis confirmed four negative prognostic factors: 3 or more days of hospitalization at the onset of an infectious episode, a diagnosis of acute myeloid leukaemia, a haematological disease status different from complete remission, the presence of pneumonia. Depending on how many factors are present, cases can be stratified into three groups, of significantly different prognosis: favourable (0 or 1 factor) 76% success; intermediate (2 factors) 52% success; unfavourable (3 or 4 factors) 19% success. At the onset of an infectious episode a subgroup of patients with a very low response rate to empirical amikacin/ceftazidime antibiotic therapy is identifiable, for whom a different therapy is indicated. Because of the high rate of proven or probable fungal infections in this group, the immediate administration of a systemic antifungal therapy, in addition to antibacterial agents, could be considered in these high-risk patients. Studies should be specifically addressed to evaluating a stratification of empirical antibiotic therapy according to risk factors present at the onset of infection.

KW - β-Lactamic-aminoglycoside combinations

KW - Febrile neutropenic cancer patients

KW - Infection

UR - http://www.scopus.com/inward/record.url?scp=0028473617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028473617&partnerID=8YFLogxK

U2 - 10.1007/BF00365733

DO - 10.1007/BF00365733

M3 - Article

C2 - 8087446

AN - SCOPUS:0028473617

VL - 2

SP - 259

EP - 265

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 4

ER -